Inhibition of ileal Na+/bile acid cotransporter by S-8921 reduces serum cholesterol and prevents atherosclerosis in rabbits

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 18, Issue 8, 1998, Pages 1304-1311

  Higaki, Junko ^a   Hara, Seijiro ^a   Takasu, Nobuo ^a   Tonda, Kanya ^a   Miyata, Kenji ^a   Shike, Tsutomu ^a   Nagata, Kiyoshi ^a   Mizui, Takuji ^a  

^a SHIONOGI AND CO LTD   (Japan)

Author keywords

Cholesterol 7 hydroxylase; Ileal bile acid cotransporter; LDL receptor; S 8921; Serum cholesterol

Indexed keywords

1 (3,4 DIMETHOXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; 1 (3,4 DIMETHYXYPHENYL) 3 (3 ETHYLVALERYL) 4 HYDROXY 6,7,8 TRIMETHOXY 2 NAPHTHOIC ACID METHYL ESTER; ANTILIPEMIC AGENT; COLESTYRAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; BILE ACID SYNTHESIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL METABOLISM; CONTROLLED STUDY; DRUG EFFECT; ENTEROHEPATIC CIRCULATION; HYPERLIPIDEMIA; LIPID ABSORPTION; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR AFFINITY;

EID: 0031842184     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.18.8.1304     Document Type: Article

References (14)

1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention: trial results, II: the relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-374.
2. Blankenhorn DH, Nessim SA, Johnson RL, Sanmarco ME, Azen SP, Cashin-Hemphill L. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-3240.
3. Brown G, Albers JJ, Fisher LD, Schaefer SM, Lin J-T, Kaplan C, Zhao X-Q, Bisson BD, Fitzpatrick VF, Dodge HT. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. N Engl J Med. 1990;323:1289-1298.
4. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
5. Ma PTS, Gil G, Südhof TC, Bilheimer DW, Goldstein JL, Brown MS. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits. Proc Natl Acad Sci U S A. 1986;83:8370-8374.
6. Reihnér E, Rudling M, Ståhlberg D, Berglund L, Ewerth S, Björkhem I, Einarsson K, Angelin B. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol. N Engl J Med. 1990;323:224-228.
7. Slater HR, Packard CJ, Bicker S, Shepherd J. Effects of cholestyramine on receptor-mediated plasma clearance and tissue uptake of human low density lipoproteins in the rabbit. J Biol Chem. 1980;255:10210-10213.
8. Chao Y-S, Yamin T-T, Alberts AW. Effects of cholestyramine on low density lipoprotein binding sites on liver membranes from rabbits with endogenous hypercholesterolemia induced by a wheat starch-casein diet. J Biol Chem. 1982;257:3623-3627.
9. Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science. 1986;232:34-47.
10. Ast M, Frishman WH. Bile acid sequestrants. J Clin Pharmacol. 1990;30:99-106.
11. Hofmann AF. The enterohepatic circulation of bile acids in health and disease. In: Sleisenger MH, Fordtran JS, eds. Gastrointestinal Disease: Pathophysiology, Diagnosis, Management. 5th ed. Philadelphia, Pa: WB Saunders Co; 1993:127-150.
12. Lack L. Properties and biological significance of the ileal bile salt transport system. Environ Health Perspect. 1979;33:79-90.
13. Dawson PA, Oelkers P. Bile acid transporters. Curr Opin Lipidol. 1995;6:109-114.
14. Lewis MC, Brieaddy LE, Root C. Effects of 2164U90 on ileal bile acid absorption and serum cholesterol in rats and mice. J Lipid Res. 1995;36:1098-1105.